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Letter and Response
A letter to the editor has been submitted to the Journal by Dr. Darrel
P. Francis and colleagues regarding the paper by Bartunek et al. (1).
Due to the nature, detail, and length of the letter and the corre-
sponding reply, the editors have made a decision to waive the usual
word limit and timelines for letters and replies so as to provide a full
airing of the issues for our readers. However, given the length of the
material, we have elected to place the letter and reply in the online
version of the issue.We encourage readers to access this material and
trust that it contributes to the editorial process.
http://dx.doi.org/10.1016/j.jacc.2013.09.012REFERENCE
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Clinical Trial (Cardiopoietic stem
Cell therapy in heart failURE)
We read with interest the recent C-CURE (Cardiopoietic stem
Cell therapy in heart failURE) trial (1) of stem cells used for the
treatment of heart failure. Completing such a multicenter trial is
a great achievement, but applying its ﬁndings either to clinical care
or future trial design might be premature, as there appear to be
some inconsistencies in the data. Discrepancies, if left unresolved,
can be problematic (2):
 How many patients were randomized? Counts ranged from
45 to 48.
 The authors’ corporate website (3) currently states that
randomization was 1:1, but Figure 1 in the paper (1) shows
counts close to 1:2; conversely, at AHA 2011, the authors
said that randomization was 2:1, but reported counts that
were close to 1:1. Can the authors please clarify the
randomization ratio?
 Once randomized to 1 arm, did any patient’s data appear
under the heading of the opposite arm? Were some patients
allocated to arms by routes other than randomization to
those arms? Are baseline characteristics and result data
regarding the trial arms, as randomized, available?
 The primary endpoint was pre-speciﬁed to be radionuclide
ejection fraction, but its results do not appear in the paper. Anew primary endpoint is described in the paper. Did all
authors agree on this change, and when?
 Regarding the data presented in the paper (1), its Online
Appendix, and the previous trial reports (see the Online
Appendix for citations), which of these various conﬂicting
versions are correct regarding ejection fraction, end-systolic
volume, end-diastolic volume, New York Heart Associa-
tion functional class, quality of life, and walk distance?
Fewer of certain events, such as arrhythmias, are reported in
the current narrative than in previous ones. Could the
authors clarify how many stem cell recipients died?
It would be extremely helpful if the authors could resolve these
and other uncertainties to aid interpretation (see the Online
Appendix for a detailed list of queries, references, and the
authors’ institutional afﬁliations).Michael Mielewczik
Graham D. Cole
Alexandra N. Nowbar
Richard Schilling
Zachary I. Whinnett
Pierre Bordachar
Peter Wilmshurst
John C. Chambers
Brian Olshansky
John Morgan
Carsten Israel
Amarjit S. Sethi
Marc van Houwelingen
John G. Cleland
Georg Schmidt
*Darrel P. Francis
*International Centre for Circulatory Health
National Heart and Lung Institute
Imperial College London
59 North Wharf Road
London W2 1LA
United Kingdom
http://dx.doi.org/10.1016/j.jacc.2013.09.013
Please note: Dr. Olshansky is a consultant for BioControl, Medtronic, Boehringer
Ingelheim, Daiichi Sankyo, and Boston Scientiﬁc; and is on the DSMB for Amarin
and Sanoﬁ Aventis. Dr. Cleland has received research grants from Servier, Novartis,
Sorin, and Amgen; is on the advisory boards for Amgen, Novartis, Servier, and
Respicardia; and speaker fees from Medtronic and Novartis. All other authors have
reported that they have no relationships relevant to the contents of this study to report.
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